- Home
- IBTA vs IRON Comparison
IBTA vs IRON Comparison
Compare IBTA & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBTA
- IRON
- Stock Information
- Founded
- IBTA 2011
- IRON 2017
- Country
- IBTA United States
- IRON United States
- Employees
- IBTA N/A
- IRON N/A
- Industry
- IBTA
- IRON Biotechnology: Pharmaceutical Preparations
- Sector
- IBTA
- IRON Health Care
- Exchange
- IBTA Nasdaq
- IRON Nasdaq
- Market Cap
- IBTA 2.2B
- IRON 1.9B
- IPO Year
- IBTA 2024
- IRON N/A
- Fundamental
- Price
- IBTA $65.34
- IRON $54.53
- Analyst Decision
- IBTA Strong Buy
- IRON Strong Buy
- Analyst Count
- IBTA 10
- IRON 10
- Target Price
- IBTA $89.20
- IRON $74.40
- AVG Volume (30 Days)
- IBTA 178.9K
- IRON 336.7K
- Earning Date
- IBTA 02-26-2025
- IRON 03-20-2025
- Dividend Yield
- IBTA N/A
- IRON N/A
- EPS Growth
- IBTA N/A
- IRON N/A
- EPS
- IBTA 0.48
- IRON N/A
- Revenue
- IBTA $368,548,000.00
- IRON N/A
- Revenue This Year
- IBTA $18.72
- IRON N/A
- Revenue Next Year
- IBTA $16.57
- IRON N/A
- P/E Ratio
- IBTA $134.54
- IRON N/A
- Revenue Growth
- IBTA 74.91
- IRON N/A
- 52 Week Low
- IBTA $41.87
- IRON $25.60
- 52 Week High
- IBTA $110.95
- IRON $77.60
- Technical
- Relative Strength Index (RSI)
- IBTA N/A
- IRON 41.25
- Support Level
- IBTA N/A
- IRON $52.21
- Resistance Level
- IBTA N/A
- IRON $55.89
- Average True Range (ATR)
- IBTA 0.00
- IRON 1.86
- MACD
- IBTA 0.00
- IRON 0.20
- Stochastic Oscillator
- IBTA 0.00
- IRON 48.48
About IBTA Ibotta Inc. Class A Common Stock
Ibotta Inc is a performance marketing platform. It allows CPG brands to deliver digital promotions to consumers through a single, convenient network called the Ibotta Performance Network (IPN).
About IRON Disc Medicine Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company that is dedicated to transforming the lives of patients with hematologic disorders. The company is building a portfolio of inventive therapeutic candidates that affect fundamental pathways of red blood cell biology. Disc Medicine is committed to developing treatments that empower and bring hope to the many patients who suffer from hematologic disease. The Company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis.